Search

Your search keyword '"Kockar, Marcelo Jiménez"' showing total 9 results
Start Over Author "Kockar, Marcelo Jiménez"
9 results on '"Kockar, Marcelo Jiménez"'

1. Long-Term Results of Bioresorbable Vascular Scaffolds in Patients With In-Stent Restenosis: The RIBS VI Study

Author

Cuesta, Javier, Pérez-Vizcayno, María José, García del Blanco, Bruno, Bosa, Francisco, Pérez de Prado, Armando, Rumoroso, José Ramón, Romaguera, Rafael, Gutiérrez, Hipólito, García Touchard, Arturo, López-Mínguez, José Ramón, Trillo, Ramiro, de la Torre Hernández, José María, Moreno, Raul, Velázquez, Maite, Moris, Cesar, Kockar, Marcelo Jiménez, Jiménez-Quevedo, Pilar, Bastante, Teresa, Val, David del, Rivero, Fernando, and Alfonso, Fernando

Published
2024
Full Text
View/download PDF

2. Hypothyroidism in Spontaneous Coronary Artery Dissection: Presentation, Clinical and Angiographic Findings, Management and Outcomes

Author

Freire, Santiago Jesús Camacho, primary, Guimaraes, Marcos García, additional, Ruíz, Ricardo Sanz, additional, Sabate, Manel, additional, Ten, Fernando Macaya, additional, Roura, Gerard, additional, Kockar, Marcelo Jiménez, additional, Del Val, David, additional, Bastante, Teresa, additional, and Alfonso, Fernando, additional

Published
2023
Full Text
View/download PDF

3. CRT-100.22 Hypothyroidism in Spontaneous Coronary Artery Dissection: Presentation, Clinical and Angiographic Findings, Management and Outcomes

Author

Camacho Freire, Santiago Jesús, primary, García Guimaraes, Marcos, additional, Sanz Ruíz, Ricardo, additional, Sabate, Manel, additional, Ten, Fernando Macaya, additional, Roura, Gerard, additional, Kockar, Marcelo Jiménez, additional, Del Val, David, additional, Bastante, Teresa, additional, and Alfonso, Fernando, additional

Published
2023
Full Text
View/download PDF

4. TCT-258 Instantaneous Wave Free Ratio for the Assessment of Intermediate Left Main Coronary Artery Stenosis: Correlations With FFR/IVUS and Prognostic Implications: The iLITRO - EPIC07 Study

Author

Camarero, Tamara Garcia, primary, Garcia-Del-Blanco, Bruno, additional, Kockar, Marcelo Jiménez, additional, Jimenez-Mazuecos, Jesus, additional, Salinas, Francisco Fernandez, additional, Lara, Josep Gomez, additional, Brugaletta, Salvatore, additional, Alfonso, Fernando, additional, Carbajal, Ricardo Palma, additional, Menchero, Antonio Gomez, additional, Millan, Raul, additional, Ponce, David Tejada, additional, Linares Vicente, Jose Antonio, additional, Ojeda, Soledad, additional, Bermudez, Eduardo Pinar, additional, Fernandez, Estefania, additional, Morales-Ponce, Francisco J., additional, Navarro, Eduardo Molina, additional, Escaned, Javier, additional, Perez de Prado, Armando, additional, and Leor, Oriol Rodriguez, additional

Published
2022
Full Text
View/download PDF

5. TCT-185 Effect of IVL in Varying Calcium Morphologies: A Prospective Study With Optical Coherence Tomography Analysis

Author

McInerney, Angela, primary, Alfonso, Fernando, additional, Travieso, Alejandro, additional, Val, David del, additional, Cerrato, Enrico, additional, Brugaletta, Salvatore, additional, Sabate, Manel, additional, Garcia de Lara, Juan, additional, Kockar, Marcelo Jiménez, additional, Nieto, Alejandro Diego, additional, Jurado-Roman, Alfonso, additional, Cepas-Guillen, Pedro L., additional, Hernandez, Jose de la Torre, additional, Bermudez, Eduardo Pinar, additional, Cubero-Gallego, Hector, additional, Vaquerizo, Beatriz, additional, Perez de Prado, Armando, additional, Jimenez Diaz, Victor Alfonso, additional, Amat-Santos, Ignacio, additional, Varbella, Ferdinando, additional, Jimenez-Quevedo, Pilar, additional, Tirado-Conte, Gabriela, additional, Macaya, Fernando, additional, Nombela-Franco, Luis, additional, Fernandez-Ortiz, Antonio, additional, Escaned, Javier, additional, and Gonzalo, Nieves, additional

Published
2022
Full Text
View/download PDF

6. Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial

Author

Romaguera, Rafael, Salinas, Pablo, Gomez-Lara, Josep, Brugaletta, Salvatore, Gómez-Menchero, Antonio, Romero, Miguel A, García-Blas, Sergio, Ocaranza, Raymundo, Bordes, Pascual, Kockar, Marcelo Jiménez, Salvatella, Neus, Jiménez-Díaz, Victor A, Alameda, Mar, Trillo, Ramiro, Lee, Dae Hyun, Martín, Pedro, López-Benito, María, Freites, Alfonso, Pascual-Tejerina, Virginia, Hernández-Hernández, Felipe, Blanco, Bruno García Del, Mohandes, Mohsen, Bosa, Francisco, Pinar, Eduardo, Roura, Gerard, Comin-Colet, Josep, Fernández-Ortiz, Antonio, Macaya, Carlos, Rossello, Xavier, Sabate, Manel, Pocock, Stuart J, Gómez-Hospital, Joan A, SUGAR trial investigators, and SUGAR trial Investigators

Subjects
equipment and supplies
Abstract

AIM: Patients with diabetes mellitus are at high risk of adverse events after percutaneous revascularization, with no differences in outcomes between most contemporary drug-eluting stents. The Cre8 EVO stent releases a formulation of sirolimus with an amphiphilic carrier from laser-dug wells, and has shown clinical benefits in diabetes. We aimed to compare Cre8 EVO stents to Resolute Onyx stents (a contemporary polymer-based zotarolimus-eluting stent) in patients with diabetes. METHODS AND RESULTS: We did an investigator-initiated, randomized, controlled, assessor-blinded trial at 23 sites in Spain. Eligible patients had diabetes and required percutaneous coronary intervention. A total of 1175 patients were randomly assigned (1:1) to receive Cre8 EVO or Resolute Onyx stents. The primary endpoint was target-lesion failure, defined as a composite of cardiac death, target-vessel myocardial infarction, and clinically indicated target-lesion revascularization at 1-year follow-up. The trial had a non-inferiority design with a 4% margin for the primary endpoint. A superiority analysis was planned if non-inferiority was confirmed. There were 106 primary events, 42 (7.2%) in the Cre8 EVO group and 64 (10.9%) in the Resolute Onyx group [hazard ratio (HR): 0.65, 95% confidence interval (CI): 0.44-0.96; Pnon-inferiority < 0.001; Psuperiority = 0.030]. Among the secondary endpoints, Cre8 EVO stents had significantly lower rate than Resolute Onyx stents of target-vessel failure (7.5% vs. 11.1%, HR: 0.67, 95% CI: 0.46-0.99; P = 0.042). Probable or definite stent thrombosis and all-cause death were not significantly different between groups. CONCLUSION: In patients with diabetes, Cre8 EVO stents were non-inferior to Resolute Onyx stents with regard to target-lesion failure composite outcome. An exploratory analysis for superiority at 1 year suggests that the Cre8 EVO stents might be superior to Resolute Onyx stents with regard to the same outcome. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT03321032.

Published
2021

7. Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial.

Author

Romaguera, Rafael, Salinas, Pablo, Gomez-Lara, Josep, Brugaletta, Salvatore, Gómez-Menchero, Antonio, Romero, Miguel A, García-Blas, Sergio, Ocaranza, Raymundo, Bordes, Pascual, Kockar, Marcelo Jiménez, Salvatella, Neus, Jiménez-Díaz, Victor A, Alameda, Mar, Trillo, Ramiro, Lee, Dae Hyun, Martín, Pedro, López-Benito, María, Freites, Alfonso, Pascual-Tejerina, Virginia, and Hernández-Hernández, Felipe

Subjects
CORONARY artery disease, PEOPLE with diabetes, DIABETES, PERCUTANEOUS coronary intervention, MYOCARDIAL infarction
Abstract

Aim Patients with diabetes mellitus are at high risk of adverse events after percutaneous revascularization, with no differences in outcomes between most contemporary drug-eluting stents. The Cre8 EVO stent releases a formulation of sirolimus with an amphiphilic carrier from laser-dug wells, and has shown clinical benefits in diabetes. We aimed to compare Cre8 EVO stents to Resolute Onyx stents (a contemporary polymer-based zotarolimus-eluting stent) in patients with diabetes. Methods and results We did an investigator-initiated, randomized, controlled, assessor-blinded trial at 23 sites in Spain. Eligible patients had diabetes and required percutaneous coronary intervention. A total of 1175 patients were randomly assigned (1:1) to receive Cre8 EVO or Resolute Onyx stents. The primary endpoint was target-lesion failure, defined as a composite of cardiac death, target-vessel myocardial infarction, and clinically indicated target-lesion revascularization at 1-year follow-up. The trial had a non-inferiority design with a 4% margin for the primary endpoint. A superiority analysis was planned if non-inferiority was confirmed. There were 106 primary events, 42 (7.2%) in the Cre8 EVO group and 64 (10.9%) in the Resolute Onyx group [hazard ratio (HR): 0.65, 95% confidence interval (CI): 0.44–0.96; P non-inferiority < 0.001; P superiority = 0.030]. Among the secondary endpoints, Cre8 EVO stents had significantly lower rate than Resolute Onyx stents of target-vessel failure (7.5% vs. 11.1%, HR: 0.67, 95% CI: 0.46–0.99; P = 0.042). Probable or definite stent thrombosis and all-cause death were not significantly different between groups. Conclusion In patients with diabetes, Cre8 EVO stents were non-inferior to Resolute Onyx stents with regard to target-lesion failure composite outcome. An exploratory analysis for superiority at 1 year suggests that the Cre8 EVO stents might be superior to Resolute Onyx stents with regard to the same outcome. Clinical trial registration ClinicalTrials.gov: NCT03321032. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results